Literature DB >> 15181252

ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function.

Arlene M Manelli1, W Blaine Stine, Linda J Van Eldik, Mary Jo LaDu.   

Abstract

Abnormalities in the processing of amyloid precursor protein to amyloid-beta (Abeta) are causal factors, and the presence of the epsilon4 allele of apolipoprotein E (apoE) is the primary risk factor for Alzheimer's disease (AD). Based, at least in part, on these genetics, the potential structural and functional interactions between these two proteins are the focus of our research. To understand the nature of the physical interactions between apoE and Abeta, we initially utilized gel-shift assays to demonstrate that native apoE2 and E3 (associated with lipid particles) form an SDS-stable complex with Abeta that is more abundant than the apoE4:Abeta complex. We further demonstrated that exogenous apoE3 but not E4 prevents Abeta-induced neurotoxicity by a process that requires apoE receptors. In addition, both exogenous apoE3 and E4 prevent Abeta-induced, glial-mediated inflammation, also via a process that requires apoE receptors. These functional effects all occur at a molar ratio of apoE to Abeta of 1:30. Because the biological activities for both apoE and Abeta are profoundly influenced by their isoform and conformation, respectively, we further investigated the idea that apoE3 and E4 differentially interact with particular aggregation species of Abeta1-42. Our overall hypothesis is that apoE has two general functions in relation to Abeta. First, apoE interacts with oligomeric Abeta via an apoE receptor-mediated process to inhibit neurotoxicity and neuroinflammation (apoE3 > apoE4) a process possibly related to binding and clearance of apoE3:oligomer complexes. Second, apoE facilitates the deposition of Abeta as amyloid (apoE4 > apoE3). We will continue to investigate the effect of apoE isoform and Abeta conformation on the structural and functional interactions between these two proteins in relation to the pathogenesis of AD. Copyright 2004 Humana Press Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15181252     DOI: 10.1385/JMN:23:3:235

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  80 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

Authors:  D M Walsh; D M Hartley; Y Kusumoto; Y Fezoui; M M Condron; A Lomakin; G B Benedek; D J Selkoe; D B Teplow
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

3.  An honorable compromise regarding amyloid in Alzheimer disease.

Authors:  R D Terry
Journal:  Ann Neurol       Date:  2001-05       Impact factor: 10.422

4.  Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease.

Authors:  Richard E Hartman; Helmut Laurer; Luca Longhi; Kelly R Bales; Steven M Paul; Tracy K McIntosh; David M Holtzman
Journal:  J Neurosci       Date:  2002-12-01       Impact factor: 6.167

5.  Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures.

Authors:  U Beffert; N Aumont; D Dea; S Lussier-Cacan; J Davignon; J Poirier
Journal:  Brain Res Mol Brain Res       Date:  1999-05-07

6.  Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease.

Authors:  A E Roher; M O Chaney; Y M Kuo; S D Webster; W B Stine; L J Haverkamp; A S Woods; R J Cotter; J M Tuohy; G A Krafft; B S Bonnell; M R Emmerling
Journal:  J Biol Chem       Date:  1996-08-23       Impact factor: 5.157

7.  Apolipoprotein E receptors mediate the effects of beta-amyloid on astrocyte cultures.

Authors:  M J LaDu; J A Shah; C A Reardon; G S Getz; G Bu; J Hu; L Guo; L J van Eldik
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

8.  Characterization of apolipoprotein J-Alzheimer's A beta interaction.

Authors:  E Matsubara; B Frangione; J Ghiso
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

9.  Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid.

Authors:  T Wisniewski; A Golabek; E Matsubara; J Ghiso; B Frangione
Journal:  Biochem Biophys Res Commun       Date:  1993-04-30       Impact factor: 3.575

10.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

View more
  41 in total

1.  Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift.

Authors:  Mary Jo LaDu; Gregory W Munson; Lisa Jungbauer; Godfrey S Getz; Catherine A Reardon; Leon M Tai; Chunjiang Yu
Journal:  Biochim Biophys Acta       Date:  2011-11-23

Review 2.  Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease.

Authors:  Maria-Paz Marzolo; Guojun Bu
Journal:  Semin Cell Dev Biol       Date:  2008-10-17       Impact factor: 7.727

3.  A flow cytometry-based in vitro assay reveals that formation of apolipoprotein E (ApoE)-amyloid beta complexes depends on ApoE isoform and cell type.

Authors:  Eleanna Kara; Jordan D Marks; Allyson D Roe; Caitlin Commins; Zhanyun Fan; Maria Calvo-Rodriguez; Susanne Wegmann; Eloise Hudry; Bradley T Hyman
Journal:  J Biol Chem       Date:  2018-06-27       Impact factor: 5.157

4.  Binding of apolipoprotein E inhibits the oligomer growth of amyloid-β peptide in solution as determined by fluorescence cross-correlation spectroscopy.

Authors:  Sonny Ly; Robin Altman; Jitka Petrlova; Yu Lin; Silvia Hilt; Thomas Huser; Ted A Laurence; John C Voss
Journal:  J Biol Chem       Date:  2013-02-21       Impact factor: 5.157

5.  The APOE ɛ4/ɛ4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients.

Authors:  Karin Hultman; Sidney Strickland; Erin H Norris
Journal:  J Cereb Blood Flow Metab       Date:  2013-05-08       Impact factor: 6.200

6.  Association of polymorphisms in the Angiotensin-converting enzyme gene with Alzheimer disease in an Israeli Arab community.

Authors:  Yan Meng; Clinton T Baldwin; Abdalla Bowirrat; Kristin Waraska; Rivka Inzelberg; Robert P Friedland; Lindsay A Farrer
Journal:  Am J Hum Genet       Date:  2006-03-16       Impact factor: 11.025

Review 7.  The vascular contribution to Alzheimer's disease.

Authors:  Robin Altman; John C Rutledge
Journal:  Clin Sci (Lond)       Date:  2010-08-05       Impact factor: 6.124

8.  APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease.

Authors:  Katherine L Youmans; Leon M Tai; Evelyn Nwabuisi-Heath; Lisa Jungbauer; Takahisa Kanekiyo; Ming Gan; Jungsu Kim; William A Eimer; Steve Estus; G William Rebeck; Edwin J Weeber; Guojun Bu; Chunjiang Yu; Mary Jo Ladu
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

9.  Endocytic pathways mediating oligomeric Abeta42 neurotoxicity.

Authors:  Chunjiang Yu; Evelyn Nwabuisi-Heath; Kevin Laxton; Mary Jo Ladu
Journal:  Mol Neurodegener       Date:  2010-05-17       Impact factor: 14.195

10.  HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide.

Authors:  Brian Giunta; Yuyan Zhou; Huayan Hou; Elona Rrapo; Francisco Fernandez; Jun Tan
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.